Clinical trial · Interventional
The Effect of Probiotics ATG-F4 in Cancer Patients
NCT06436976CI-TRIAL-00077630unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with advanced colorectal cancer or pancreatic cancer who are receiving oxaliplatin-based chemotherapy will be included. The research participants in this study will consume probiotics along with safety and anti-cancer agent side effect-related questionnaires, blood, and fecal sample collection for up to 12 weeks from the date of registration. The total duration of participation for research subjects is 12 weeks.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LT-002 (Lactobacillus reuteri ATG-F4 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- LT-002 (Lactobacillus reuteri ATG-F4) arm
- description
- The group that will be consuming probiotics (LT-002 (Lactobacillus reuteri ATG-F4)) for 12 weeks. The subjects will take a daily intake of 4 x 10\^10 colony forming unit (CFU) of LT-002.
- interventionNames
- Drug: LT-002 (Lactobacillus reuteri ATG-F4
Primary outcomes (1)
- measure
- Changes of Body weight (Kg)
- timeFrame
- baseline, 4 weeks, 8 weeks
- description
- Body weight measured by Bio-electrical Impedance Analysis
Secondary outcomes (13)
- measure
- Lean body mass
- timeFrame
- baseline, 4 weeks, 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with advanced colorectal cancer or pancreatic cancer who are undergoing treatment with Oxaliplatin-based chemotherapy at Chungnam National University Hospital, including both newly diagnosed and recurrent cases. * Aged 19 years or older. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 points. * Expected life expectancy of at least 3 months. * Ability to understand the requirements of the clinical trial and willingness to sign the informed consent form. Exclusion Criteria: * Presence of known brain metastases. * Malignant bowel obstruction requiring surgical intervention. * Uncontrolled, active infections, symptomatic congestive heart failure, unstable angina, cardiac arrhythmias, or any psychiatric/social conditions that may limit compliance with the study requirements. * Partial or complete intestinal obstruction. * Pregnant or lactating women. * Use of antibiotics, antifungals, or antiviral agents on more than one occasion within the past month. * Consumption of probiotics products or fermented milk more than twice within the past month. * Patients with neurological or psychiatric disorders.
References
Publications (0)
Data not yet available
No reference posted for this study.